Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study (Q44655765)
Jump to navigation
Jump to search
scientific article published on 26 February 2015
Language | Label | Description | Also known as |
---|---|---|---|
English | Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study |
scientific article published on 26 February 2015 |
Statements
1 reference
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study (English)
1 reference
B J Monk
1 reference
P Ghatage
1 reference
T Parekh
1 reference
E Henitz
1 reference
R Knoblauch
1 reference
A S Matos-Pita
1 reference
A Nieto
1 reference
Y C Park
1 reference
P S Cheng
1 reference
W Li
1 reference
R Favis
1 reference
D Ricci
1 reference
A Poveda
1 reference
26 February 2015
1 reference
1 reference
26
1 reference
5
1 reference
914-920
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference